Annual report
7733.TEDINET S100QZRG
Period2022-04-01 → 2023-03-31
Filed2023-06-20
StandardIFRS
ConsolidatedYes
Data checks19 of 19 passed
Amended by S100RV9X (2023-09-19).
Key figures · 158
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥881.9bn | 2022-04-01 → 2023-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥750.1bn | 2021-04-01 → 2022-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥730.5bn | 2020-04-01 → 2021-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥755.2bn | 2019-04-01 → 2020-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥793.9bn | 2018-04-01 → 2019-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥186.6bn | 2022-04-01 → 2023-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥146.2bn | 2021-04-01 → 2022-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥182.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥141.7bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥76.8bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥86.6bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥20.1bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥143.4bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥115.7bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥12.9bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥51.7bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥8.1bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥143.6bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥116.0bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥1.51T | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.36T | at 2022-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.18T | at 2021-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥1.02T | at 2020-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥932.0bn | at 2019-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥867.1bn | at 2023-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥846.6bn | at 2022-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥641.2bn | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥511.4bn | at 2022-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥395.5bn | at 2021-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥640.1bn | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥510.2bn | at 2022-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥394.3bn | at 2021-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥370.7bn | at 2020-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥441.2bn | at 2019-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥169.3bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥205.5bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥302.6bn | at 2022-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥217.5bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥162.7bn | at 2020-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥114.6bn | at 2019-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥98.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥169.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥124.1bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥133.5bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥66.9bn | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥58.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥71.0bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥118.9bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥62.4bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥60.3bn | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥143.2bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥40.7bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | ¥40.8bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥19.5bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥82.9bn | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥113.22 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥90.22 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥10.05 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥39.37 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥5.97 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥113.08 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥90.17 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥10.04 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥39.36 | 2019-04-01 → 2020-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥5.96 | 2018-04-01 → 2019-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥510.62 | at 2023-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥400.75 | at 2022-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥306.72 | at 2021-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥288.39 | at 2020-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥323.06 | at 2019-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 42.4% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 37.6% | at 2022-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 33.3% | at 2021-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 36.5% | at 2020-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 47.3% | at 2019-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 24.9% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 25.6% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 3.4% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 12.7% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 1.8% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 32,844 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 31,557 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 31,653 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 35,174 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 35,124 | at 2019-03-31d | Cons. | Number of employees |
| Revenue | ¥380.0bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥378.6bn | 2021-04-01 → 2022-03-31 | Standalone | Net sales |
| Revenue | ¥344.1bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥375.3bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥376.8bn | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥82.0bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | ¥45.4bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥152.3bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥57.2bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥49.0bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥13.3bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥44.0bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥165.4bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥95.0bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥130.3bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥84.8bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥8.5bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥9.9bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥30.2bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥973.6bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥900.9bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥826.6bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥771.0bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥745.8bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥555.3bn | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥543.7bn | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥418.3bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥357.2bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥349.8bn | at 2021-03-31d | Standalone | Net assets |
| Net assets / equity | ¥376.2bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥471.4bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥4m | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥46m | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥102.88 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥66.13 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥6.64 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥7.51 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥22.13 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥102.76 | 2022-04-01 → 2023-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥66.1 | 2021-04-01 → 2022-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥6.64 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥7.51 | 2019-04-01 → 2020-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥22.12 | 2018-04-01 → 2019-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥16 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥14 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥12 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥10 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥30 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥333.48 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥280.3 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥271.69 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥292.24 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥344.8 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 42.9% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.6% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 42.3% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 48.7% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 63.1% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 33.6% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 24.0% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.4% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.3% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.5% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 1,266,179,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,299,294,000 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,370,915,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 1,370,915,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 342,713,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 2,727 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 3,478 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 4,775 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 7,146 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 7,024 | at 2019-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 37
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2023-03-31 | 559 pure |
| Otherother segments | capex | 2022-04-01 → 2023-03-31 | ¥1.4bn |
| Otherother segments | segment assets | at 2023-03-31 | ¥20.6bn |
| Otherother segments | segment profit | 2022-04-01 → 2023-03-31 | −¥914m |
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥11.7bn |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | ¥479.2bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥28.9bn |
| Endoscopicreportable segment | employees | at 2023-03-31 | 14308 pure |
| Endoscopic Solutionsreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥43.0bn |
| Endoscopic Solutionsreportable segment | segment assets | at 2023-03-31 | ¥555.5bn |
| Endoscopic Solutionsreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥152.8bn |
| Scientific Solutionsreportable segment | employees | at 2023-03-31 | 4124 pure |
| Therapeuticreportable segment | employees | at 2023-03-31 | 8448 pure |
| Therapeutic Solutionsreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥15.9bn |
| Therapeutic Solutionsreportable segment | segment assets | at 2023-03-31 | ¥453.0bn |
| Therapeutic Solutionsreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥63.7bn |
| —segment total | capex | 2022-04-01 → 2023-03-31 | ¥60.3bn |
| —segment total | segment assets | at 2023-03-31 | ¥1.03T |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥215.5bn |
| Otherother segments | capex | 2021-04-01 → 2022-03-31 | ¥997m |
| Otherother segments | segment assets | at 2022-03-31 | ¥20.9bn |
| Otherother segments | segment profit | 2021-04-01 → 2022-03-31 | −¥2.0bn |
| Reconciling Itemsreconciling | capex | 2021-04-01 → 2022-03-31 | ¥8.4bn |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | ¥430.6bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥45.8bn |
| Endoscopic Solutionsreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥40.4bn |
| Endoscopic Solutionsreportable segment | segment assets | at 2022-03-31 | ¥493.6bn |
| Endoscopic Solutionsreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥133.2bn |
| Therapeutic Solutionsreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥16.3bn |
| Therapeutic Solutionsreportable segment | segment assets | at 2022-03-31 | ¥412.9bn |
| Therapeutic Solutionsreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥60.8bn |
| —segment total | capex | 2021-04-01 → 2022-03-31 | ¥57.8bn |
| —segment total | segment assets | at 2022-03-31 | ¥927.4bn |
| —segment total | segment profit | 2021-04-01 → 2022-03-31 | ¥192.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2023-03-31 | 6 pure |
| Endoscopicreportable segment | employees | at 2023-03-31 | 566 pure |
| Therapeuticreportable segment | employees | at 2023-03-31 | 279 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,881
| Item | Context | Value | Unit |
|---|---|---|---|
| Price earnings ratio (5-year summary) | CurrentYearDuration_NonConsolidatedMember | 22.5 | |
| Payout ratio (5-year summary) | Prior4YearDuration_NonConsolidatedMember | 1.356 | |
| Payout ratio (5-year summary) | Prior3YearDuration_NonConsolidatedMember | 1.332 | |
| Payout ratio (5-year summary) | Prior2YearDuration_NonConsolidatedMember | 1.807 | |
| Payout ratio (5-year summary) | Prior1YearDuration_NonConsolidatedMember | 0.212 | |
| Payout ratio (5-year summary) | CurrentYearDuration_NonConsolidatedMember | 0.156 | |
| Number of employees | Prior4YearInstant_NonConsolidatedMember | 7024 | |
| Number of employees | Prior3YearInstant_NonConsolidatedMember | 7146 | |
| Number of employees | Prior2YearInstant_NonConsolidatedMember | 4775 | |
| Number of employees | Prior1YearInstant_NonConsolidatedMember | 3478 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 2727 | |
| Total shareholder return | Prior4YearInstant_NonConsolidatedMember | 1.198 | |
| Total shareholder return | Prior3YearInstant_NonConsolidatedMember | 1.564 | |
| Total shareholder return | Prior2YearInstant_NonConsolidatedMember | 2.298 | |
| Total shareholder return | Prior1YearInstant_NonConsolidatedMember | 2.359 | |
| Total shareholder return | CurrentYearInstant_NonConsolidatedMember | 2.354 | |
| Total return on share price index | Prior4YearInstant_NonConsolidatedMember | 0.950 | |
| Total return on share price index | Prior3YearInstant_NonConsolidatedMember | 0.859 | |
| Total return on share price index | Prior2YearInstant_NonConsolidatedMember | 1.221 | |
| Total return on share price index | Prior1YearInstant_NonConsolidatedMember | 1.246 | |
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | 1.318 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E02272-000EndoscopicReportableSegmentMember | 14308 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E02272-000EndoscopicReportableSegmentMember | 251 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E02272-000TherapeuticReportableSegmentMember | 8448 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E02272-000TherapeuticReportableSegmentMember | 161 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E02272-000ScientificSolutionsReportableSegmentMember | 4124 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E02272-000ScientificSolutionsReportableSegmentMember | 151 | |
| Number of employees | CurrentYearInstant_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 559 | |
| Average number of temporary workers | CurrentYearInstant_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 3 | |
| Number of employees | CurrentYearInstant_CorporateSharedMember | 5405 | |
| Average number of temporary workers | CurrentYearInstant_CorporateSharedMember | 219 | |
| Number of employees | CurrentYearInstant | 32844 | |
| Average number of temporary workers | CurrentYearInstant | 785 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 2727 | |
| Average age years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 42.86 | |
| Average length of service years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 13.85 | |
| Average annual salary information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 9652126 | JPY |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E02272-000EndoscopicReportableSegmentMember | 566 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E02272-000TherapeuticReportableSegmentMember | 279 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 6 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 1876 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 2727 | |
| Research and development expenses research and development activities | CurrentYearDuration | 76900000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E02272-000EndoscopicSolutionsReportableSegmentMember | 44300000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E02272-000TherapeuticSolutionsReportableSegmentMember | 22700000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_OtherReportableSegmentsMember | 9900000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 72000000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E02272-000EndoscopicSolutionsReportableSegmentMember | 43000000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E02272-000TherapeuticSolutionsReportableSegmentMember | 15900000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_OtherReportableSegmentsMember | 1400000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 19 of 19 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |